Active Biotech's Annual Report 2009 is now available for download at www.activebiotech.com <http://www.activebiotech.com/> <http://www.activebiotech.com>. The Annual Report will only be digitally distributed. <mailto:> Lund, April 20, 2010 Active Biotech AB (publ) Tomas Leanderson President & CEO For further information, please contact: Göran Forsberg Vice President Investor Relations & Business Development Tel +46 (0)46 19 11 54 Active Biotech AB (OMX NORDIC: ACTI), headquartered in Sweden, is a biotechnology company with R&D focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, primarily renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex(TM) for RA. Please visit www.activebiotech.com for more information. Active Biotech AB (Corp. Reg. No. 556223-9227) Box 724, SE-220 07 Lund Tel: +46 46 19 20 00 Fax: +46 46 19 11 00 Active Biotech is obligated to publish the information contained in this press release in accordance with the Swedish Securities Market Act. This information was provided to the media for publication on April 20, 2010, at 10:00 a.m. [HUG#1405573]